Use of a catheter-based inflatable device (balloon ostial dilation) for the treatment of chronic rhinosinusitis in the sinus being considered for dilation may be medically necessary when all of the following criteria are met:

- Patient is 18 years of age or older (see Policy Guidelines for younger ages)
- Chronic rhinosinusitis with ALL of the following:
  - Present for at least 12 continuous weeks
  - Without nasal polyps
  - Negatively impacts the quality of life
  - Patient has one or more of the following:
    - Facial pain-pressure-fullness with either of the following conditions:
      - Mucopurulent nasal drainage (anterior, posterior, or both)
      - Nasal obstruction (congestion)
    - Decrease sense of smell with either of the following conditions:
      - Mucopurulent nasal drainage (anterior, posterior, or both)
      - Nasal obstruction (congestion)
- Optimal medical therapy has been attempted and failed, as indicated by all of the following:
  - Allergy evaluation, education, and optimal treatment when indicated
  - Two 10-day courses of antibiotics, or one prolonged course of at least 21 days duration
  - Decongestants when indicated
  - Topical and/or systemic corticosteroids for at least 8 weeks
  - Saline nasal irrigation for at least 8 consecutive weeks
  - Treatment of rhinitis medicamentosa (rebound nasal congestion due to extended use of topical decongestants), when present
  - Education on environmental irritants including tobacco smoke.
- Clinical and radiographic documentation of persistent inflammation following optimal medical therapy (see Policy Guidelines).

The use of balloon ostial dilation for the treatment of chronic rhinosinusitis is considered investigational when all of the above criteria are not met.

The use of balloon ostial dilation for the treatment of recurrent acute rhinosinusitis is considered investigational.

Policy Guidelines

Inflammation should be documented by all of the following:

- Nasal endoscopy showing purulent (not clear) mucus or edema in the middle meatus, anterior ethmoid, or sphenoid region.
- CT scan of the paranasal sinuses showing mucosal thickening of greater than 3mm, opacification, or air-fluid levels.

Balloon Ostial Dilation (BOD) used in combination with Functional Endoscopic Sinus Surgery (FESS)

- BOD when used as a tool during functional endoscopic sinus surgery (FESS) in the same sinus cavity is considered to be an integral part of the FESS procedure.
• When BOD is used as an adjunct to FESS (defined as FESS on one sinus and BOD on another sinus in the same patient during the same operation) medical necessity criteria for BOD apply to the sinus being considered for BOD.

Considerations for the use of BOD in children under age 18 years include all of the following:
• FDA labeling for several 510(k) cleared devices includes use in children 17 years of age and under and is indicated to dilate sinus ostia and spaces associated with the maxillary sinus for diagnostic and therapeutic procedures.
• A 2014 AAO-HNS Clinical Consensus Statement on Pediatric Chronic Rhinosinusitis had near consensus on the safety of BOD in children but did not reach a consensus on efficacy.
• American Academy of Pediatrics Clinical Practice Guidelines only address the diagnosis and treatment of acute bacterial rhinosinusitis.

Coding
Effective January 1, 2020, the following codes have been revised:
The following are specific category I CPT codes for these procedures. These codes may be used to describe balloon sinus ostial dilation when no other surgical intervention has been performed on the same sinus site:
• 31295: Nasal/sinus endoscopy, surgical, with dilation (e.g., balloon dilation); maxillary sinus ostium, transnasal or via canine fossa
• 31296: Nasal/sinus endoscopy, surgical, with dilation (e.g., balloon dilation); frontal sinus ostium
• 31297: Nasal/sinus endoscopy, surgical, with dilation (e.g., balloon dilation); sphenoid sinus ostium

Effective January 1, 2020, the following code has been revised:
The following CPT code is specific to balloon dilation done in both the frontal and sphenoid sinuses:
• 31298: Nasal/sinus endoscopy, surgical, with dilation (e.g., balloon dilation); frontal and sphenoid sinus ostia

This procedure might also be coded using the following CPT code. It could be submitted alone or with other nasal/sinus endoscopy codes:
• 31299: Unlisted procedure, accessory sinuses

If balloon sinus ostial dilation is performed with cutting tools such as curettes and forceps, the procedure might use the following CPT codes. Plans should be aware of these possibilities. In those instances, the balloon dilation would be considered inclusive/incidental to the procedure.
• 31256: Nasal/sinus endoscopy, surgical, with maxillary antrostomy
• 31276: Nasal/sinus endoscopy, surgical, with frontal sinus exploration, including removal of tissue from frontal sinus, when performed
• 31287: Nasal/sinus endoscopy, surgical, with sphenoidotomy

In the Medicare outpatient hospital setting, the following HCPCS code may be used for the device:
• C1726: Catheter, balloon dilatation, nonvascular

Description
Balloon ostial dilation (also known as balloon sinuplasty) is proposed as an alternative to traditional endoscopic sinus surgery for patients with chronic rhinosinusitis who fail medical management. The procedure involves placing a balloon in the sinus ostium and inflating the balloon to stretch the opening. It can be performed as a stand-alone procedure or as an adjunctive procedure to functional endoscopic sinus surgery (FESS).
Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Some state or federal mandates (e.g., Federal Employee Program [FEP]) prohibits plans from denying Food and Drug Administration (FDA)-approved technologies as investigational. In these instances, plans may have to consider the coverage eligibility of FDA-approved technologies on the basis of medical necessity alone.

Regulatory Status

In 2008, the Relieva™ Sinus Balloon Catheter (Acclarent, Menlo Park, CA) was cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process. The FDA determined that this device was substantially equivalent to existing devices for use in dilating the sinus ostia and paranasal spaces in adults and maxillary sinus spaces in children. Subsequent devices developed by Acclarent have also been cleared by the FDA through the 510(k) process. They include the Relieva Spin Sinus Dilation System® (cleared in 2011) and the Relieva Seeker Balloon Sinuplasty System® (cleared in 2012).

In 2008, the FinESS™ Sinus Treatment (Entellus Medical, Maple Grove, MN) was cleared for marketing by the FDA through the 510(k) process. The indication noted is to access and treat the maxillary ostia/ethmoid infundibulum in adults using a transantral approach (FDA product code: EOB). The bony sinus outflow tracts are remodeled by balloon displacement of adjacent bone and paranasal sinus structures. Two other balloon sinus ostial dilation devices, the ENTrigue® Sinus Dilation System (ENTrigue Surgical, acquired by more recently by Smith & Nephew), and the XprESS™ Multi-Sinus Dilation Tool, also received 510(k) clearance in 2012.

In 2013, a sinus dilation system (Medtronic Xomed, Jacksonville, FL), later named the NuVent™ EM Balloon Sinus Dilation System, was cleared for marketing by the FDA through the 510(k) process for use in conjunction with a Medtronic computer-assisted surgery system when surgical navigation or image-guided surgery may be necessary to locate and move tissue, bone, or cartilaginous tissue surrounding the drainage pathways of the frontal, maxillary, or sphenoid sinuses.

Also in 2013, a sinus dilation system (Smith & Nephew), later named the Ventera™ Sinus Dilation System, was cleared for marketing through the 510(k) process to access and treat the frontal recesses, sphenoid sinus ostia, and maxillary ostia/ethmoid infundibula in adults using a transnasal approach.

Table 1 summarizes the currently FDA cleared balloon sinus dilation devices.

FDA product code: LRC.
# Table 1. Balloon Ostial Dilation Devices Cleared by the US Food and Drug Administration

<table>
<thead>
<tr>
<th>Device</th>
<th>Manufacturer</th>
<th>510(k) No.</th>
<th>Date Cleared</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>MESIRE - Balloon Sinus Dilatation System</td>
<td>Meril Life Sciences</td>
<td>K172737</td>
<td>12/12/2017</td>
<td>Sinus Ostia Dilation</td>
</tr>
<tr>
<td>Relieva SpinPlus Nav Balloon Sinuplasty System</td>
<td>Acclarent Inc.</td>
<td>K171687</td>
<td>9/5/2017</td>
<td>Sinus Ostia Dilation</td>
</tr>
<tr>
<td>XprESS ENT Dilatation System</td>
<td>Entellus Medical Inc.</td>
<td>K163509</td>
<td>4/5/2017</td>
<td>Sinus Ostia Dilation</td>
</tr>
<tr>
<td>Relieva Ultirma Nav Sinus Balloon Catheter</td>
<td>Acclarent Inc.</td>
<td>K161698</td>
<td>10/24/2016</td>
<td>Sinus Ostia Dilation</td>
</tr>
<tr>
<td>Vent-Os Sinus Dilation Family</td>
<td>Sinusys Corp.</td>
<td>K160770</td>
<td>6/29/2016</td>
<td>Sinus Ostia Dilation</td>
</tr>
<tr>
<td>Relieva Scout Multi-Sinus Dilation System</td>
<td>Acclarent Inc.</td>
<td>K153341</td>
<td>2/12/2016</td>
<td>Sinus Ostia Dilation</td>
</tr>
<tr>
<td>XprESS Multi-Sinus Dilation System</td>
<td>Entellus Medical Inc.</td>
<td>K152434</td>
<td>11/20/2015</td>
<td>Sinus Ostia Dilation</td>
</tr>
<tr>
<td>DSS Sinusplasty Balloon Catheter</td>
<td>Intuit Medical Products LLC</td>
<td>K143738</td>
<td>8/27/2015</td>
<td>Sinus Ostia Dilation</td>
</tr>
<tr>
<td>Relieva SpinPlus Balloon Sinuplasty System</td>
<td>Acclarent Inc.</td>
<td>K143541</td>
<td>4/22/2015</td>
<td>Sinus Ostia Dilation</td>
</tr>
<tr>
<td>XprESS Multi-Sinus Dilation Tool</td>
<td>Entellus Medical Inc.</td>
<td>K142252</td>
<td>10/17/2014</td>
<td>Sinus Ostia Dilation</td>
</tr>
<tr>
<td>Relieva Scout Multi-Sinus Dilation System</td>
<td>Acclarent Inc.</td>
<td>K140160</td>
<td>2/20/2014</td>
<td>Sinus Ostia Dilation</td>
</tr>
</tbody>
</table>

## Rationale

### Background

**Chronic Rhinosinusitis (CRS)**

Chronic rhinosinusitis (CRS) is characterized by purulent nasal discharge, usually, without fever, that persists for weeks to months. Symptoms of congestion often accompany the nasal discharge. There also may be mild pain and/or a headache. Thickening of mucosa may restrict or close natural openings between sinus cavities and the nasal fossae, although symptoms vary considerably because of the location and shape of these sinus ostia.

### Treatment

Estimates have suggested approximately 30 million individuals in the United States suffer from CRS. Most cases are treated with medical therapy, but surgical drainage is an option for patients who fail to respond to medical therapy. Functional endoscopic sinus surgery (FESS) has become an important aspect for surgical management of chronic sinusitis, although evidence from randomized controlled trials is limited. For this procedure, a fiberoptic nasal endoscope is used to visualize the sinus ostia, and any obstruction found is corrected. This procedure restores patency and allows air and mucous transport through the natural ostium. Approximately 350,000 FESS procedures are done each year in the United States for CRS.

A newer procedure, balloon ostial dilatation can be used as an alternative or as an adjunct to FESS for those with CRS. The goal of this technique, when used as an alternative to FESS, is to improve sinus drainage using a less invasive approach. When used as an adjunct to FESS, it is intended to facilitate and/or increase access to the sinuses. The procedure involves placing a guidewire in the sinus ostium, advancing a balloon over the guidewire, and then stretching the opening by inflating the balloon. The guidewire location is confirmed with fluoroscopy or with direct transillumination of the targeted sinus cavity. General anesthesia may be needed for this procedure to minimize patient movement.

The maxillary sinus creates a unique challenge. The maxillary ostia, located within the ethmoid infundibulum, often cannot be accessed transnasally without excising a portion of the uncinate process. An alternative approach to the maxillary ostia is through the sinus, via the canine fossa.
A guidewire can be advanced from within the maxillary sinus to the nasal fossa. The dilating balloon can enlarge the ostia while deflecting the uncinate process.

**Outcomes**

To quantify the severity of CRS and to assess treatment response, various outcomes measures can be used, including radiologic scores, endoscopic grading, and patient-reported quality of life (QOL) measures.

The Lund-Mackay scoring system uses radiologist-rated information derived from computed tomography scans to assess opacification of the sinus cavities, generating a score from 0 to 12.\(^1,2\)

Disease-specific patient-reported QOL scores include the commonly used Sino-Nasal Outcome Test-20 (SNOT-20), which is a validated questionnaire for which patients complete 20 symptom questions on a categorical scale (0 [no bother] to 5 [worst symptoms can be]). Average rankings can be reported over all 20 symptoms, as well as by 4 subclassified symptom domains. The SNOT-22, a variation of the SNOT-20, includes 2 additional questions (on “nasal obstruction” and “loss of smell and taste”). The minimal clinically important difference for the SNOT-22 has been estimated to be 8.9 points.\(^3\)

Additionally, QOL has been reported using overall health-related QOL scores, such as the 36-Item Short-Form Health Survey. That tool includes 8 scaled scores on various health domains, which are transformed into a 0-to-100 scale (100 corresponding to best health).

**Literature Review**

Evidence reviews assess the clinical evidence to determine whether the use of a technology improves the net health outcome. Broadly defined, health outcomes are length of life, quality of life, and ability to function including benefits and harms. Every clinical condition has specific outcomes that are important to patients and to managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens, and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of a technology, 2 domains are examined: the relevance and the quality and credibility. To be relevant, studies must represent one or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. RCTs are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

**Balloon Ostial Dilation as a Stand-Alone Procedure for Patients with Chronic Rhinosinusitis**

**Clinical Context and Test Purpose**

The purpose of balloon ostial dilation (BOD) as a stand-alone procedure in patients with chronic rhinosinusitis (CRS) is to provide a treatment option that is an alternative to or an improvement on existing therapies, such as medical management and functional endoscopic sinus surgery (FESS).

The question addressed in this evidence review is: Does balloon ostial dilation as a stand-alone procedure improve the net health outcome for patients with chronic rhinosinusitis? The following PICO was used to select literature to inform this review.
Patients
The relevant population of interest is individuals 18 years of age and older with CRS, defined as an inflammatory condition involving the paranasal sinuses and linings of the nasal passages characterized by purulent nasal discharge, nasal obstruction, facial pain or pressure, and reduction in sense of smell, usually without fever, that persists for 12 weeks or longer.

Intervention
The treatment being considered is BOD (also known as balloon sinuplasty). The procedure involves placing a balloon in the sinus ostium and inflating it to stretch the opening. BOD can be performed in the operating room or in an office setting under local anesthesia.

Comparators
Comparators of interest include medical management (steroids, antibiotics, or decongestants) and FESS.

Outcomes
The general outcomes of interest are symptoms, change in disease status, quality of life, and treatment-related morbidity.

To quantify the severity of CRS and to assess treatment response, various outcomes measures can be used, including radiologic scores, endoscopic grading, and patient-reported quality of life measures. The primary outcome measures relevant for the treatment of chronic rhinosinusitis (CRS) are patient-reported symptoms and quality of life. Examiner evaluation of the nasal and sinus appearance and polyp size may provide some information about treatment outcomes, but these evaluations are limited by the lack of universally accepted standards.

Disease-specific patient-reported quality of life scores include the commonly used Sino-Nasal Outcome Test-20 (SNOT-20), which is a validated questionnaire for which patients complete 20 symptom questions on a categorical scale (0 [no bother] to 5 [worst symptoms can be]). Average rankings can be reported over all 20 symptoms, as well as by 4 subclassified symptom domains. The possible range of SNOT-20 scores is 0 to 5, with a higher score indicating a greater rhinosinusitis-related health burden. The impact of treatment is measured by calculating the difference between SNOT-20 scores before and after treatment. A SNOT-20 change score of 0.8 or greater is believed to be clinically meaningful. The SNOT-22, a variation of the SNOT-20, includes 2 additional questions (on “nasal obstruction” and “loss of smell and taste”). The minimally important difference in SNOT-22 is considered to be 8.9 points.

The Lund-Mackay scoring system uses radiologist-rated information derived from computed tomography scans to assess opacification of the sinus cavities, generating a score from 0 to 24. Although CT scans can provide an objective measure, often they do not correlate well with symptoms.

Six months to 1 year of follow-up is considered necessary to demonstrate efficacy.

Study Selection Criteria
Methodologically credible studies were selected using the following principles:
- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies;
- To assess longer term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought;
- Studies with duplicative or overlapping populations were excluded.
Review of Evidence

Systematic Review

Levy et al (2016) conducted a systematic review and meta-analysis of BOD for CRS (Table 2). Studies of balloon ostial dilation in combination with FESS were included if they reported data on subgroups of patients undergoing BOD as a standalone procedure. Reviewers included 17 studies; 11 of these provided data for meta-analysis. Two RCTs were included. The other studies were prospective or retrospective observational studies.

Results of the meta-analyses conducted by Levy et al are summarized in Table 3. Change from baseline in quality of life, as measured by SNOT-20 scores was clinically and statistically significant in patients who received BOD. Secondary outcome measures of postoperative complications, debridements, and revision surgery were heterogeneously reported without the consistency or power needed to make statistically valid comparisons. The reviewers concluded that BOD for the treatment of CRS in the reported study population had positive impact on patient quality of life as assessed by a validated measurement. Improvements exceeded the threshold of 0.8 and could be considered clinically significant. The reviewers also concluded that additional information was needed to determine the role of BOD in specific patient populations such as those with moderate to advanced sinus disease, to compare the incidence of postoperative complications and debridements in patients who receive BOD compared with FESS, and additional study of patients outcomes following BOD in the operating room versus the office setting.

Table 2. Systematic Review of Balloon Ostial Dilation for Chronic Rhinosinusitis- Characteristics

<table>
<thead>
<tr>
<th>Study</th>
<th>Search Dates</th>
<th>Studies</th>
<th>Participants</th>
<th>N (Range)</th>
<th>Design</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levy et al (2016)</td>
<td>1996-2014</td>
<td>17</td>
<td>Adults &gt;18 years undergoing transnasal paranasal sinus BOD for CRS</td>
<td>1032 (6-328)</td>
<td>RCT (n=2) • Prospective cohort (n=9) • Retrospective cohort (n=6)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(11 provided data for meta-analysis)</td>
<td></td>
<td></td>
<td>Varied (&lt;6 months to &gt;1 year)</td>
</tr>
</tbody>
</table>

BOD: balloon ostial dilation; CRS: chronic rhinosinusitis; RCT: randomized controlled trial; N: sample size

Table 3. Systematic Review of Balloon Ostial Dilation for Chronic Rhinosinusitis- Results

<table>
<thead>
<tr>
<th>Study</th>
<th>Quality of Life (SNOT-20)</th>
<th>CT Findings (Lund-McKay Score)</th>
<th>Recovery Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levy et al (2016)</td>
<td>Change from baseline ≤6 months</td>
<td>BOD vs FESS Improvement from baseline</td>
<td>BOD vs FESS Number days to return of regular activity following intervention</td>
</tr>
<tr>
<td></td>
<td>242</td>
<td>1.45 (0.99, 1.91)</td>
<td>140</td>
</tr>
<tr>
<td></td>
<td>214</td>
<td>1.41 (1.07, 1.74)</td>
<td>194</td>
</tr>
<tr>
<td></td>
<td>N analyzed 214</td>
<td>-0.42 (-1.39, 1.55)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>P (P-value) 78% (.001)</td>
<td>1.15 (0.87-1.43)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>59% (.04)</td>
<td>30% (.22)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>76% (.04)</td>
<td>NA</td>
<td></td>
</tr>
</tbody>
</table>

SNOT-20: Sino-Nasal Outcome Test-20; CT: computed tomography; BOD: balloon ostial dilation; FESS: functional endoscopic sinus surgery; N: sample size; CI: confidence interval

Randomized Controlled Trials

BOD as a standalone procedure for patients with CRS has been evaluated in 4 RCTs reported in 6 publications (Tables 2 and 3). Two studies were published after the systematic review conducted by Levy et al.8,9

The largest RCT is the REMODEL (randomized evaluation of maxillary antrostomy versus ostial dilation efficacy through long-term follow-up) trial. REMODEL results at 6, 12, and 24 months have...
been reported in 3 publications.\textsuperscript{10,11,8} This was an industry-sponsored RCT that compared BOD as a stand-alone procedure with FESS. A total of 105 patients with CRS or RARS and failure of medical therapy were randomized to BOD or FESS. Patients with gross sinonasal polyposis were excluded. Balloon ostial dilation was performed with the Entellus device, which is labeled for a transantral approach. FESS consisted of maxillary antrostomy and uncinectomy with or without anterior ethmoidectomy. Thirteen patients withdrew consent before treatment, 11 (21\%) in the FESS group and 2 (4\%) in the BOD group. The primary outcomes were the change in SNOT-20 scores at 6-month follow-up and mean number of postoperative debridements. Secondary outcomes included recovery time, complication rates, and rates of revision surgery.

Noninferiority analysis was performed for the primary outcome of change in symptom score and superiority analyses were performed on the debridement outcome.

Ninety-one patients who were enrolled in REMODEL were available at 6-month follow-up.\textsuperscript{10} The improvement in the mean SNOT-20 score was 1.67 (1.10) in the balloon dilation group and 1.60 (0.96) in the FESS arm (P = .001) for noninferiority. Postoperative debridements were more likely in the FESS group with a mean of 1.2 (1.0) compared to a mean of 0.1 (0.6) in the balloon dilation group (P < .001 for superiority in the balloon arm). Patients in the BOD arm returned to normal daily activities faster (1.6 days vs 4.8 days, P = .002 for superiority) and required fewer days of prescription pain medications (0.9 days vs 2.8 days, P = .002 for superiority) with balloon dilation. There were no major complications in either group, and 1 patient in each group required revision surgery.

Bikhazi et al (2014) reported 1-year follow-up from the REMODEL trial.\textsuperscript{11} Eighty-nine (96.7\%) subjects were available at 1 year. Improvement in the mean SNOT-20 score was 1.64 in the balloon dilation arm and 1.65 in the FESS arm (P < .001 for noninferiority). During the year postprocedure, both groups had fewer self-reported rhinosinusitis episodes (mean reduction in episodes, 4.2 in the balloon arm vs 3.5 in the FESS arm; P < .001).

Final REMODEL results were reported in Chandra et al (2016).\textsuperscript{8} This publication included results up to 2 years post procedure for subjects in the REMODEL trial, along with an additional 30 subjects treated with FESS or in-office balloon sinus dilation, for a reported total of 61 FESS patients and 74 BOD patients. Follow-up data were available for 130, 66, and 25 patients at 12, 18, and 24 months, respectively. Details about group-specific treatment received and loss to follow-up were not reported for the additional 30 patients not included in the REMODEL trial. The BOD group required 0.2 debridements per patient compared with 1.0 per patient in the FESS group (P < .001).

Mean change in SNOT-20 score from baseline to 12-month follow-up was -1.59 (P < .001) and -1.60 (P < .001) for the BOD and FESS groups, respectively, which was considered clinically significant. These changes were maintained at 24 months. At 18 months, overall revision rates were 2.7\% in the balloon dilation group and 6.9\% in the FESS group.

In addition to REMODEL, three smaller RCTs provide evidence on the comparison of BOD to FESS in patients with CRS.

Minni et al (2018) published a prospective, randomized study comparing BOD and traditional endoscopic sinus surgery (ESS) for CRS of the frontal sinuses.\textsuperscript{9} At three Italian hospitals, 102 individuals (148 sinuses) were enrolled with mild involvement of the frontal sinus, the average post-procedure SNOT-20 scores for the BOD and ESS groups were 24.6 and 27.54 (P = .42), respectively; for patients with moderate/severe involvement, the scores were 33.47 and 30.71 (P < .05), respectively. Post-procedure Lund-Mackay scores were 0.58 (BOD) and 0.54 (ESS; P = .30) in the mild group and 0.53 (BOD) and 0.78 (ESS; P = .38) in the moderate/severe group.

Bizaki et al (2014) reported on results from a RCT that compared balloon ostial dilation with FESS among patients with symptomatic chronic or recurrent acute rhinosinusitis.\textsuperscript{4} Results were not reported separately for patients with CRS and RARS, and the study authors stated, “For this study,
both CRS and RARS were considered to be one disease. The trial enrolled 46 subjects, 4 of whom withdrew; the analysis included 42 patients (n=21 in each group; statistical power calculations not reported). Both treatment groups demonstrated significant improvements in SNOT-22 scores from baseline to post procedure. There were no differences in change in total SNOT-22 scores between groups at 3 months post procedure.

Achar et al (2012) was an open-label pilot study of 24 patients with CRS who had failed medical therapy and were scheduled for surgery. Patients were randomized to BOD or to FESS and followed for 24 weeks. The primary outcome measures were changes in SNOT-20 scores and clearance time using the saccharin test. Both groups improved significantly on both measures. The degree of improvement was greater for the balloon dilatation group than for the FESS group on both the SNOT-20 score (43.8 vs 29.7, P <.03) Patients who received BOD were able to return to normal activities sooner than those who received FESS (2.2 days vs 5.0 days; P NR). Adverse events were not reported.

### Table 4. RCTs of BOD compared to FESS in CRS: Characteristics

<table>
<thead>
<tr>
<th>Study; Trial</th>
<th>Countries</th>
<th>Sites</th>
<th>Dates</th>
<th>Participants</th>
<th>Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>REMODEL</td>
<td>US</td>
<td>10</td>
<td>2011-2014</td>
<td>135 adults with medically refractory chronic (68%) or recurrent acute (32%) rhinosinusitis according to AAO-HNS clinical practice guidelines; all met criteria for medically necessary FESS. Patients with nasal polyps were excluded.</td>
<td>BOD (office setting) N=74</td>
</tr>
<tr>
<td>Bizaki 2014</td>
<td>Finland</td>
<td>1</td>
<td>NR</td>
<td>42 adults with CRS or RARS who fulfilled indications for surgical treatment. Patients with visible polyps in nasal direct endoscopy were excluded.</td>
<td>BOD N=21</td>
</tr>
<tr>
<td>Achar 2012</td>
<td>UK</td>
<td>2</td>
<td>NR</td>
<td>24 adults with CRS diagnosed as per EPOS guidelines who failed medical treatment (topical steroids</td>
<td>BOD N=12</td>
</tr>
</tbody>
</table>
Table 5. RCTs of BOD Compared to FESS in CRS: Results

<table>
<thead>
<tr>
<th>Study</th>
<th>Quality of Life</th>
<th>Symptoms</th>
<th>CT Scan Results</th>
<th>Adverse Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outcome measure</td>
<td>Mean change from baseline in SNOT-20 score</td>
<td>Time to return to normal daily activities</td>
<td>Overall Ostial Patency</td>
<td>N=89 patients, 169 ostia</td>
</tr>
<tr>
<td>Number analyzed</td>
<td>N=91 at 6 months, 89 at 12 months</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

REMODEL: randomized evaluation of maxillary antrostomy versus ostial dilation efficacy through long-term follow-up; RCT: randomized controlled trial; BOD: balloon ostial dilation; FESS: functional endoscopic sinus surgery; CRS: chronic rhinosinusitis; NCT: National Clinical Trial; AAO-HNS: American Academy of Otolaryngology - Head and Neck Surgery; N: sample size; RARS: recurrent acute rhinosinusitis

### BOD

<table>
<thead>
<tr>
<th></th>
<th>6 months: 1.67 (1.10)</th>
<th>1.6 days</th>
<th>6 months: NR</th>
<th>No complications</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>12 months: 1.64 (1.06)</td>
<td></td>
<td>12 months: 96.7% (88/91)</td>
<td>28.0% nasal bleeding</td>
</tr>
<tr>
<td></td>
<td>24 months: -1.65</td>
<td></td>
<td>1 (2.1%) revision surgery through 1 year</td>
<td></td>
</tr>
</tbody>
</table>

### FESS

<table>
<thead>
<tr>
<th></th>
<th>6 months: 1.60 (0.96)</th>
<th>4.8 days</th>
<th>6 months: NR</th>
<th>No complications</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>12 months: 1.65 (0.94)</td>
<td></td>
<td>12 months: 98.7% (77/78)</td>
<td>54.8% nasal bleeding</td>
</tr>
<tr>
<td></td>
<td>24 months: -1.45</td>
<td></td>
<td>1 (2.4%) revision surgery through 1 year</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Between-group p-value</th>
<th>6 months: P &lt;0.001</th>
<th>0.002</th>
<th>12 months: P = NS</th>
<th>Nasal bleeding: P =0.01</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>12 months: 0.01 (95% CI -0.43 to 0.44); BOD noninferior to FESS (P &lt;0.0001)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>24 months:</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Minni et al 2018

<table>
<thead>
<tr>
<th>Outcome measure</th>
<th>Mean decrease in SNOT-20 at 12 months</th>
<th>Mean decrease in Lund-McKay score at 12 months</th>
<th>102 patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number analyzed</td>
<td>mild: 105 sinuses</td>
<td>severe: 33 sinuses</td>
<td>105 sinuses mild: 105 sinuses severe: 33 sinuses</td>
</tr>
</tbody>
</table>

Reproduction without authorization from Blue Shield of California is prohibited
Study | Quality of Life | Symptoms | CT Scan Results | Adverse Events |
---|---|---|---|---|
BOD | mild: 36.34 | mild: 1.1 | No major complications |
| severe: 41.32 | severe: 2.57 | |
FESS | mild: 38.0 | mild: 1.03 | No major complications |
| severe: 36.57 | severe: 2.29 | |
Between group difference | mild: P =.42 | mild: P =.30 | |
| severe: P <.05 | severe: P =.38 | |
Bodaki et al (2014) | Outcome measure | Mean decrease in SNOT-22 from baseline to 3 months | NR | N=42 |
| Number analyzed | N=42 | No major complications |

| Study | Quality of Life | Symptoms | CT Scan Results | Adverse Events |
---|---|---|---|---|
BOD | 21.47 | No major complications |
FESS | 20.95 | No major complications |
Between group difference | P =.587 | P >.05 |
Achar et al (2012) | Outcome measure | Mean decrease in SNOT-22 from baseline to 6 months | NR | NR |
| Number analyzed | N=24 | Mean time to get back to routine activities |
| BOD | 43.83 (SD 15.17) | 2.2 days | |
| FESS | 29.66 (SD 12.33) | 5.0 days | |
Between group difference | P =.026 | NR |

REMODOE: randomized evaluation of maxillary antrostomy versus ostial dilation efficacy through long-term follow-up; RCT: randomized controlled trial; BOD: balloon ostial dilation; FESS: functional endoscopic sinus surgery; SNOT-20: Sino-Nasal Outcome Test-20; NR: not reported

Tables 6 and 7 summarize the limitations of the RCTs of BOD in patients with CRS. A major limitation of these trials was a lack of blinding, combined with the use of subjective outcome measures, and small sample sizes. However, objective measures (CT findings), additional evidence from observational studies, and consistency and magnitude of effects across studies make these limitations less concerning.
### Table 6. Study Relevance Limitations

<table>
<thead>
<tr>
<th>Study</th>
<th>Population</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Outcomes</th>
<th>Follow-Up</th>
</tr>
</thead>
<tbody>
<tr>
<td>REMODEL</td>
<td>3. Source and characteristics of patients added to the study for final results was unclear</td>
<td>1. Randomization of added patients occurred outside of key study</td>
<td>1. Differential loss post-randomization between study arms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Minni et al 2018 a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Achar et al 2014 b</td>
<td>3. Combined patients with CRS and RARS; results not reported separately by diagnosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bizaki et al 2014 c</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

REMODEL: randomized evaluation of maxillary antrostomy versus ostial dilation efficacy through long-term follow-up.

The evidence limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

a Population key: 1. Intended use population unclear; 2. Clinical context is unclear; 3. Study population is unclear; 4. Study population not representative of intended use.
b Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest.
c Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively.
d Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. No CONSORT reporting of harms; 4. Not establish and validated measurements; 5. Clinical significant difference not prespecified; 6. Clinical significant difference not supported.
e Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms.

### Table 7. Study Design and Conduct Limitations

<table>
<thead>
<tr>
<th>Study</th>
<th>Allocation</th>
<th>Blinding</th>
<th>Selective Reporting</th>
<th>Data Completeness</th>
<th>Power</th>
<th>Statistical</th>
</tr>
</thead>
<tbody>
<tr>
<td>REMODEL</td>
<td>1, 2. Not blinded</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Minni et al 2018 a</td>
<td>3. Method not described</td>
<td>1,2, 3. No information on blinding</td>
<td>1. Not registered</td>
<td></td>
<td>Results reported by sinuses (N=148), not by patient (N=102)</td>
<td></td>
</tr>
<tr>
<td>Achar et al 2014 b</td>
<td>1, 2. Not blinded</td>
<td>1. Not registered</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bizaki et al 2014 c</td>
<td>3. Method not described</td>
<td>1,2, 3. No information on blinding</td>
<td>1. Not registered</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

REMODEL: randomized evaluation of maxillary antrostomy versus ostial dilation efficacy through long-term follow-up.

The evidence limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.
a Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation...
Observational Study of Adverse Events
A retrospective cohort study used data from a large commercial insurance database to examine adverse events reported in patients who underwent balloon dilation (n=2851), FESS (n=11,955), or a hybrid procedure (n=1234) between 2011 and 2014. The primary outcomes were surgical complication and revision rates within 6 months of the initial surgery. The overall complication rate was 7.35% with FESS and 5.26% with balloon dilation. The 6-month revision rates for balloon dilation, FESS, and hybrid surgeries were 7.89%, 16.85%, and 15.15%, respectively. Almost all revisions occurred with FESS regardless of primary procedure. However, differences in revision rates could have been due to differences in disease severity in patients who received FESS versus balloon dilation. Major complications included orbital complications, cerebrospinal fluid leak, severe epistaxis, and requirement for revision.

Section Summary: Balloon Ostial Dilation as a Stand-Alone Procedure for Patients with Chronic Rhinosinusitis
Four RCTs have compared BOD to FESS for patients with CRS. The best evidence is from the REMODEL trial, which showed statistically and clinically significant improvements in quality of life for up to 24 months, as measured by the validated SNOT-20 scale. REMODEL results are supported by smaller RCTs, multiple comparative observational studies, and a systematic review showing improvements in quality of life, CT outcomes, and shorter recovery time with BOD than FESS. In a retrospective cohort study that used data from a large commercial insurance database to examine adverse events in patients who underwent BOD (n=2851) or FESS (n=11,955), the overall complication rate was 5.26% with BOD and 7.35% with FESS.

Balloon Ostial Dilation as a Stand-Alone Procedure for Patients with Recurrent Acute Rhinosinusitis
Clinical Context and Test Purpose
The purpose of balloon ostial dilation (BOD) as a stand-alone procedure in patients with recurrent acute rhinosinusitis (RARS) is to provide a treatment option that is an alternative to or an improvement on existing therapies, such as medical management and functional endoscopic sinus surgery.

The question addressed in this evidence review is: Does BOD improve the net health outcome for patients with RARS?

The following PICO was used to select literature to inform this review.

Patients
The relevant population of interest is individuals 18 years of age and older with RARS. The American Academy of Otolaryngology-Head and Neck Surgery defines RARS as 4 or more episodes per year of acute bacterial rhinosinusitis without signs or symptoms of rhinosinusitis between episodes. Each episode of acute bacterial rhinosinusitis should meet the following diagnostic criteria:

- Acute rhinosinusitis that is caused by, or is presumed to be caused by, bacterial infection. A clinician should diagnose ABRS when: symptoms or signs of acute rhinosinusitis fail to
improve within 10 days or more beyond the onset of upper respiratory symptoms, or symptoms or signs of acute rhinosinusitis worsen within 10 days after an initial improvement (double worsening)

- Confirming a true bacterial episode of rhinosinusitis is desirable, but not essential, for substantiating an underlying diagnosis of RARS

**Intervention**

The therapy being considered is balloon ostial dilation as a stand-alone procedure. The procedure involves placing a balloon in the sinus ostium and inflating it to stretch the opening. Balloon ostial dilation can be performed in the operating room or in an office setting under local anesthesia.

**Comparators**

Comparators of interest include medical management and functional endoscopic sinus surgery.

**Outcomes**

The general outcomes of interest are symptoms, change in disease status, quality of life, and treatment-related morbidity.

To quantify the severity of RARS and to assess treatment response, various outcomes measures can be used, including radiologic scores, endoscopic grading, and patient-reported quality of life measures. The primary outcome measures relevant for the treatment of RARS are patient-reported symptoms and quality of life. Examiner evaluation of the nasal and sinus appearance and polyp size may provide some information about treatment outcomes, but these evaluations are limited by the lack of universally accepted standards.

Disease-specific patient-reported quality of life scores include the commonly used Sino-Nasal Outcome Test-20 (SNOT-20), which is a validated questionnaire for which patients complete 20 symptom questions on a categorical scale (0 [no bother] to 5 [worst symptoms can be]). Average rankings can be reported over all 20 symptoms, as well as by 4 subclassified symptom domains. The possible range of SNOT-20 scores is 0 to 5, with a higher score indicating a greater rhinosinusitis-related health burden. The impact of treatment is measured by calculating the difference between SNOT-20 scores before and after treatment. A SNOT-20 change score of 0.8 or greater is believed to be clinically meaningful.

The Chronic Sinusitis Survey (CSS) is a measure of symptoms and medication usage over an 8-week recall period. The CSS includes 3 questions regarding symptoms and 3 regarding medication usage, yielding a total score as well as symptom and medication subscores evaluated as secondary endpoints. CSS total score ranges from 0 to 100 in which a low CSS score represents greater symptoms and/or medication usage. The minimally clinically significant difference on the CSS has not been established.

A decrease in the number of acute infections occurring over a specified time period is used as an outcome measure in some studies.

Six months to 1 year of follow-up is considered necessary to demonstrate efficacy.

**Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies;
- To assess longer term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
Studies with duplicative or overlapping populations were excluded.

**Review of Evidence**

**Randomized Controlled Trials**
Two RCTs of BOD reported results separately for patients with RARS (Table 8). A third RCT, reported by Bizaki et al (2014) compared BOD with FESS among patients with CRS or RARS, but results were not reported separately by diagnosis. The study authors stated, "For this study, both CRS and RARS were considered to be one disease." This trial is discussed in the previous section on BOD for CRS.

In the REMODEL trial, 32% (N=29) of the patients enrolled had a diagnosis of RARS. The CABERNET (Comparison of Balloon Sinuplasty In-Office Versus Medical Management for Recurrent Acute Sinusitis Patients) trial compared BOD plus medical therapy to medical therapy alone in 59 patients with RARS. Both trials used the AAO-HNS diagnosis of RARS to select eligible patients: 4 or more episodes of acute rhinosinusitis in the past 12 months. In CABERNET, evidence of sinus or osteomeatal complex disease during an acute episode from a CT scan was also required for enrollment. In REMODEL, all patients met criteria for medically necessary FESS, but explicit CT requirements for patients with RARS were not specified.

Results of the RCTs of patients with RARS are summarized in Table 9. Among the 29 patients diagnosed with RARS in the REMODEL trial, there was a significant improvement in quality of life for those who received either BOD or FESS, and the difference between treatment arms was not significant (P = 0.838). Twelve-month results from REMODEL were reported in Bikhaiz et al (2014). Data were not reported separately by diagnosis, but the publication states, "At 1 year, symptom improvement in each of the four subgroups [including based on diagnosis] remained statistically significant (P < 0.001) in both treatment arms and there was no difference (P = NS) in improvement between patients who underwent balloon dilation or FESS." REMODEL results were not reported separately by diagnosis for secondary outcomes, or for the primary outcome (SNOT-20) at 24 months.

In Sikand et al (2019), the primary outcome was the difference between arms in change in Chronic Sinusitis Survey (CSS) score from baseline to 24 weeks. The change in CSS was significantly greater in the BOD group compared to the control group (mean change 37.3 vs 21.8; P = 0.0424). The study authors did not specify whether this was considered clinically significant. Patients in the BOD group had a lower mean number of sinus infections through the 24-week followup period (0.2 vs 0.9; P = 0.015). Durability of the outcome measure differences was demonstrated up to 48 weeks. After the 24-week followup period, 18 of 30 patients who were randomized to the control arm elected to receive BOD. Of those who crossed over at 24 weeks, 0 reported no change or worsening of symptoms, 3 reported improved symptoms but still used nasal sprays at high rates, 4 had improved symptoms to varying degrees but were not eliminated, and 1 reported a sinus infection just before their 24-week visit. There was one procedure-related serious adverse event in the BOD group (the patient sought treatment for a headache in the emergency department the evening after the procedure), two possibly procedure-related nonserious adverse events, and no device-related adverse events.

### Table 8. Summary of Key RCT Characteristics- Balloon Ostial Dilation for Recurrent Acute Rhinosinusitis

<table>
<thead>
<tr>
<th>Study/ Trial</th>
<th>Countries</th>
<th>Sites</th>
<th>Dates</th>
<th>Participants</th>
<th>Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>REMODEL</td>
<td>US</td>
<td>10</td>
<td>2011-2014</td>
<td>Adults with medically refractory chronic (68%) or recurrent acute (32%) rhinosinusitis according to</td>
<td>Active Comparator</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BOD (office setting) N=16</td>
</tr>
</tbody>
</table>

Table 8 includes data from different studies examining the effectiveness of balloon ostial dilation (BOD) for treating recurrent acute rhinosinusitis (RARS). The table highlights key characteristics of the randomized controlled trials (RCTs) that evaluated BOD versus medical therapy or FESS in patients with RARS. The studies vary in terms of the inclusion criteria, interventions, and outcomes measured. The tables and text provide a comprehensive overview of the evidence supporting the use of BOD in managing RARS, including the reported improvements in quality of life and reduced sinus infections in both treatment arms. The REMODEL trial, for instance, demonstrated a significant improvement in quality of life for patients treated with BOD or FESS, with no significant difference between the treatment arms. The CABERNET trial also showed positive outcomes for BOD plus medical therapy compared to medical therapy alone. However, the results were not reported separately by diagnosis, and no explicit CT requirements were specified for patients with RARS. The table also notes the procedural details, such as the number of patients randomized, the duration of follow-up, and the type of adverse events reported in the studies. These findings collectively support the use of BOD in the management of RARS, with further research needed to confirm these outcomes and address the potential clinical significance of the reported improvements.
### Table 9. Summary of Key RCT Results- Balloon Ostial Dilation for Recurrent Acute Rhinosinusitis

<table>
<thead>
<tr>
<th>Study</th>
<th>Countries</th>
<th>Sites</th>
<th>Dates</th>
<th>Participants</th>
<th>Interventions</th>
<th>Adverse Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sikand et al (2019)</td>
<td>US</td>
<td>3</td>
<td>2013-2015</td>
<td>Adults with a diagnosis of recurrent acute rhinosinusitis, defined as having 4 or more episodes of acute bacterial rhinosinusitis within the previous 12 months, characterized by signs or symptoms of acute rhinosinusitis 10 or more days beyond the onset of upper respiratory symptoms, or within 10 days after initial improvement (double worsening)</td>
<td>BOD plus medical management; N=30</td>
<td>Sham procedure plus medical management; N=29</td>
</tr>
<tr>
<td>REMODEL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Mean change from baseline in SNOT-20 score; N=29</td>
<td>Mean number per year, year before to year after treatment</td>
</tr>
<tr>
<td>BOD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6 months: (RARS subgroup): -1.57 (+1.08); P &lt;0.001</td>
<td>5.1 to 0.9</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>12 months: Data not reported separately for patients with RARS. &quot;At 1 year, symptom improvement in each of the four subgroups [including based on diagnosis] remained statistically significant (P &lt;0.001) in both treatment arms and there was no</td>
<td>P &lt;0.0001</td>
</tr>
</tbody>
</table>

RCT: randomized controlled trial.
<table>
<thead>
<tr>
<th>Study</th>
<th>Quality of Life</th>
<th>Acute Exacerbations</th>
<th>Adverse Events</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>difference (P = NS) in improvement between patients who underwent balloon dilation or FESS.</td>
<td>24 months: NR separately for patients with RARS</td>
<td></td>
</tr>
<tr>
<td>FESS</td>
<td>6 months (RARS subgroup): -1.64 (-0.90); P &lt; 0.0001</td>
<td>4.5 to 0.8</td>
<td></td>
</tr>
<tr>
<td></td>
<td>24 months: NR separately for patients with RARS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Between-group p-value</td>
<td>6 months: .838</td>
<td>.258</td>
<td></td>
</tr>
</tbody>
</table>

Sikand et al (2019) [16, CABERNET NCT01714687]

**Outcome measure**
- **Number analyzed**
  - Total score: 37.3 (SD 24.4)
  - Symptom subscore: 48.7 (SD 28.7)
  - Medication subscore: 26.0 (SD 26.6)

**Sham + medical management**
- Total score: 21.8 (29.0)
- Symptom subscore: 27.2 (40.1)
- Medication subscore: 16.4 (24.0)

**Between-group p-value**
- Total score:.0424
- Symptom subscore:.0484
- Medication subscore:.2607

CI: confidence interval; HR: hazard ratio; NNT: number needed to treat; OR: odds ratio; RCT: randomized controlled trial; RR: relative risk.

Tables 10 and 11 summarize the limitations of the RCTs of BOD in patients with RARS. Major limitations include no blinding of outcome assessors, a very small number of patients studied, and variation in the comparators and outcome measures used across the studies.
Table 10. Study Relevance Limitations

<table>
<thead>
<tr>
<th>Study</th>
<th>Populationa</th>
<th>Interventionb</th>
<th>Comparatorc</th>
<th>Outcomesd</th>
<th>Follow-Upe</th>
</tr>
</thead>
<tbody>
<tr>
<td>REMODEL</td>
<td>3. Some outcomes not reported separately by diagnosis of RARS</td>
<td>1. Randomization of added patients occurred outside of key study</td>
<td>Medical regimen not standardized (customized by the treating investigator)</td>
<td>5. Clinically significant difference on primary outcome (CSS) not specified</td>
<td>1. Differential loss post-randomization between study arms</td>
</tr>
</tbody>
</table>

Sikand et al (2019)

- CABERNET

CABERNET: Comparison of Balloon Sinuplasty In-Office Versus Medical Management for Recurrent Acute Sinusitis Patients; REMODEL: randomized evaluation of maxillary antrostomy versus ostial dilation efficacy through long-term follow-up.

The evidence limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

da Population key: 1. Intended use population unclear; 2. Clinical context is unclear; 3. Study population is unclear; 4. Study population not representative of intended use.
b Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest.
c Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively.
d Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. No CONSORT reporting of harms; 4. Not establish and validated measurements; 5. Clinical significant difference not prespecified; 6. Clinical significant difference not supported.
e Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms.

Table 11. Study Design and Conduct Limitations

<table>
<thead>
<tr>
<th>Study</th>
<th>Allocationa</th>
<th>Blindingb</th>
<th>Selective Reportingc</th>
<th>Data Completenessd</th>
<th>Powere</th>
<th>Statisticalf</th>
</tr>
</thead>
<tbody>
<tr>
<td>REMODEL</td>
<td>1, 2. Not blinded</td>
<td></td>
<td></td>
<td>Not powered to detect differences by RARS subgroup</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CABERNET</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CABERNET: Comparison of Balloon Sinuplasty In-Office Versus Medical Management for Recurrent Acute Sinusitis Patients; REMODEL: randomized evaluation of maxillary antrostomy versus ostial dilation efficacy through long-term follow-up.

The evidence limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.
d Data Completeness key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).
e Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.
f Statistical key: 1. Analysis is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event;
2. Analysis is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated.

Section Summary: Balloon Ostial Dilation as a Standalone Procedure for Patients with Recurrent Acute Rhinosinusitis

Two RCTs of BOD reported results separately for patients with RARS; one (REMODEL) compared BOD to FESS in a subgroup of 29 patients, and the other (CABERNET) compared BOD to medical care in 59 patients. In the REMODEL study BOD was non-inferior to FESS on measures of quality of life at 6 months and 12 months post-procedure; 24-month results were not reported separately for patients with RARS. One RCT comparing balloon ostial dilation plus medical care to medical care alone in patients with RARS found significantly improved quality of life and lower mean number of sinus infections after 24 months in the balloon dilation group. A third RCT included a mix of patients with chronic and RARS and found improved quality of life compared to FESS, but results were not reported separately by diagnosis.

Summary of Evidence

For individuals with CRS who receive BOD as a stand-alone procedure, the evidence includes RCTs, observational studies, and systematic reviews. Relevant outcomes are symptoms, change in disease status, quality of life, and treatment-related morbidity. In the REMODEL RCT, balloon ostial dilation was non-inferior to FESS for patients with chronic rhinosinusitis. Durability of effect was demonstrated in uncontrolled studies that followed patients who received balloon dilation for up to 24 months. Evidence from RCTs is supported by multiple observational studies and a systematic review showing improved quality of life following BOD. In a retrospective cohort study that used data from a large commercial insurance database to examine adverse events reported in patients who underwent balloon dilation (n=2851), FESS (n=11,955), or a hybrid procedure (n=1234), the overall complication rate was 7.35% with FESS and 5.26% with balloon dilation. The evidence is sufficient to determine the effects of the technology on health outcomes.

For individuals with RARS who receive BOD as a stand-alone procedure, the evidence includes RCTs. Relevant outcomes are symptoms, change in disease status, quality of life, and treatment-related morbidity. In the REMODEL study of BOD compared to FESS, 32% of patients were diagnosed with recurrent acute rhinosinusitis (N=29). Balloon ostial dilation was non-inferior to FESS on measures of quality of life at 6 months and 12 months post-procedure. One RCT comparing balloon ostial dilation plus medical care to medical care alone in patients with RARS found significantly improved quality of life and lower mean number of sinus infections after 24 months in the balloon dilation group. A third RCT included a mix of patients with chronic and RARS and found improved quality of life compared to FESS, but results were not reported separately by diagnosis. The body of evidence is limited by the small number of patients studied, unblinded outcome assessment, lack of appropriate comparators, and heterogeneity in outcome measures used. The evidence is insufficient to determine the effects of the technology on health outcomes.

Supplemental Information

Practice Guidelines and Position Statements

American Academy of Otolaryngology - Head and Neck Surgery et al

In 2018, the American Academy of Otolaryngology—Head and Neck Surgery (AAO-HNS) published a clinical consensus statement on balloon dilation of the sinuses. Participating subgroups included the Triologic Society, the American Rhinologic Society, the American Academy of Otolaryngic Allergy, and the American Academy of Allergy, Asthma & Immunology. The expert panel used Delphi method surveys to assess consensus on proposed statements. Statements achieving a mean score of 7.00 or higher and having no more than 1 outlier (2 or more Likert points from the mean in either direction) met criteria for consensus. Strong consensus was defined as a mean Likert score of 8.00 or higher with no outliers. The following statements met consensus; statements reaching strong consensus are highlighted.
Patient Criteria:

- Balloon dilation is not appropriate for patients who are without both sinonasal symptoms and positive findings on CT. (Strong consensus)
- Balloon dilation is not appropriate for the management of headache in patients who do not otherwise meet the criteria for chronic sinusitis or recurrent acute sinusitis. (Strong consensus)
- Balloon dilation is not appropriate for the management of sleep apnea in patients who do not otherwise meet the criteria for chronic sinusitis or recurrent acute sinusitis. (Strong consensus)
- CT scanning of the sinuses is a requirement before balloon dilation can be performed. (Strong consensus)
- Balloon dilation is not appropriate for patients with sinonasal symptoms and a CT that does not show evidence of sinonasal disease.
- Balloon dilation can be appropriate as an adjunct procedure to FESS in patients with chronic sinusitis without nasal polyps.
- There can be a role for balloon dilation in patients with persistent sinus disease who have had previous sinus surgery.
- There is a role for balloon sinus dilation in managing patients with recurrent acute sinusitis as defined in the AAO-HNSF guideline based on symptoms and CT evidence of ostial occlusion and mucosal thickening.

Perioperative Considerations:

- Surgeons who consider reusing devices intended for dilation of the sinuses should understand the regulations set forth by the FDA for reprocessing such devices and ensure that they are followed. (Strong consensus)
- Balloon dilation can be performed under any setting as long as proper precautions are taken and appropriate monitoring is performed.
- Balloon dilation can be performed under local anesthesia with or without sedation.

Outcome:

- Balloon dilation can improve short-term quality-of-life outcomes in patients with limited CRS without polyposis.
- Balloon dilation can be effective in frontal sinusitis.

The AAO-HNS updated its statement on balloon ostial dilation, reaffirming its 2010 position statement: “Sinus ostial dilation...is a therapeutic option for selected patients with chronic rhinosinusitis...This approach may be used alone...or in conjunction with other instruments...”

In 2015, the Academy’s Foundation updated its 2007 clinical practice guidelines on adult sinusitis, which do not discuss surgical therapy or use of balloon sinuplasty.

The National Institute for Health and Care Excellence

In 2008, a guidance on balloon catheter dilation of paranasal sinus ostia from the National Institute for Health and Care Excellence (NICE) stated:

- “Current evidence on the short-term efficacy of balloon catheter dilation of paranasal sinus ostia for chronic sinusitis is adequate and raises no major safety concerns.
- This procedure should only be carried out by surgeons with experience of complex sinus surgery, and specific training in both the procedure and the use of fluoroscopy.
- Publication of long-term outcomes will be helpful in guiding the future use of this technique. NICE may review the procedure upon publication of further evidence.”

In 2016, NICE published a recommendation on the use of the XprESS Multi-Sinus Dilation System for the treatment of chronic rhinosinusitis:

1.1 “The case for adopting the XprESS multi-sinus dilation system for treating uncomplicated chronic sinusitis after medical treatment has failed is supported by the evidence. Treatment with
XpRESS leads to a rapid and sustained improvement in chronic symptoms, fewer acute episodes and improved quality of life which is comparable to functional endoscopic sinus surgery (FESS). XpRESS should be considered in patients with uncomplicated chronic sinusitis who do not have severe nasal polyposis. In these patients, XpRESS works as well as FESS, is associated with faster recovery times, and can more often be done under local anaesthesia.

The recommendation was based on the results of the REMODEL study: the committee "considered that the evidence from REMODEL demonstrated that balloon dilation (with either XpRESS or FinESS) is clinically non-inferior to FESS in terms of alleviating symptoms in patients with uncomplicated chronic sinusitis." Single-arm observational studies were of lower quality but were consistent with the findings of the REMODEL study.

American Rhinologic Society
A position statement, revised in 2017, from the American Rhinologic Society, stated that sinus ostial dilation is "a therapeutic option for selected patients with chronic rhinosinusitis (CRS) ... who have failed appropriate medical therapy."21

U.S. Preventive Services Task Force Recommendations
Not applicable.

Medicare National Coverage
There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials
A search of ClinicalTrials.gov in December 2019 did not identify any ongoing or unpublished trials that would likely influence this review.

References


**Documentation for Clinical Review**

**Please provide the following documentation:**

- History and physical and/or consultation notes including:
  - Clinical indications/justification of procedure
  - Previous treatment(s), duration, and response(s)
  - Treatment plan
- Pertinent radiological imaging results (i.e., CT and/or MRI and/or PET)

**Post Service (in addition to the above, please include the following):**

- Procedure report(s)

**Coding**

This Policy relates only to the services or supplies described herein. Benefits may vary according to product design; therefore, contract language should be reviewed before applying the terms of the Policy. Inclusion or exclusion of codes does not constitute or imply member coverage or provider reimbursement.

**MN/IE**

The following services may be considered medically necessary in certain instances and investigational in others. Services may be considered medically necessary when policy criteria are met. Services may be considered investigational when the policy criteria are not met or when the code describes application of a product in the position statement that is investigational.

<table>
<thead>
<tr>
<th>Type</th>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT®</td>
<td>31256</td>
<td>Nasal/sinus endoscopy, surgical, with maxillary antrostomy</td>
</tr>
<tr>
<td>CPT®</td>
<td>31276</td>
<td>Nasal/sinus endoscopy, surgical, with frontal sinus exploration, including removal of tissue from frontal sinus, when performed</td>
</tr>
<tr>
<td>CPT®</td>
<td>31287</td>
<td>Nasal/sinus endoscopy, surgical, with sphenoidotomy</td>
</tr>
<tr>
<td>Type</td>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>------</td>
<td>-------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td>31295</td>
<td>Nasal/sinus endoscopy, surgical, with dilation (e.g., balloon dilation); maxillary sinus ostium, transnasal or via canine fossa <strong>(Code revision effective 1/1/2020)</strong></td>
</tr>
<tr>
<td></td>
<td>31296</td>
<td>Nasal/sinus endoscopy, surgical, with dilation (e.g., balloon dilation); frontal sinus ostium <strong>(Code revision effective 1/1/2020)</strong></td>
</tr>
<tr>
<td></td>
<td>31297</td>
<td>Nasal/sinus endoscopy, surgical, with dilation (e.g., balloon dilation); sphenoid sinus ostium <strong>(Code revision effective 1/1/2020)</strong></td>
</tr>
<tr>
<td></td>
<td>31298</td>
<td>Nasal/sinus endoscopy, surgical, with dilation (e.g., balloon dilation); frontal and sphenoid sinus ostia <strong>(Code revision effective 1/1/2020)</strong></td>
</tr>
<tr>
<td></td>
<td>31299</td>
<td>Unlisted procedure, accessory sinuses</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>HCPCS</strong> C1726 Catheter, balloon dilatation, nonvascular</td>
</tr>
</tbody>
</table>

**Policy History**

This section provides a chronological history of the activities, updates and changes that have occurred with this Medical Policy.

<table>
<thead>
<tr>
<th>Effective Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>01/11/2008</td>
<td>BCBSA Medical Policy adoption</td>
</tr>
<tr>
<td>10/01/2010</td>
<td>Policy revision</td>
</tr>
<tr>
<td>01/04/2011</td>
<td>Coding Update</td>
</tr>
<tr>
<td>03/30/2015</td>
<td>Policy title change from Balloon Sinuplasty for Treatment of Chronic Sinusitis Policy revision without position change</td>
</tr>
<tr>
<td>05/01/2016</td>
<td>Policy revision without position change</td>
</tr>
<tr>
<td>10/01/2016</td>
<td>Policy revision without position change</td>
</tr>
<tr>
<td>07/01/2017</td>
<td>Policy title change from Balloon Ostial Dilation for Treatment of Chronic Sinusitis Policy revision without position change</td>
</tr>
<tr>
<td>02/01/2018</td>
<td>Coding update</td>
</tr>
<tr>
<td>04/01/2018</td>
<td>Policy revision without position change</td>
</tr>
<tr>
<td>05/01/2019</td>
<td>Policy revision without position change</td>
</tr>
<tr>
<td>03/01/2020</td>
<td>Coding update</td>
</tr>
<tr>
<td>07/01/2020</td>
<td>Annual review. No change to policy statement.</td>
</tr>
<tr>
<td>09/01/2020</td>
<td>Policy statement, guidelines and literature updated.</td>
</tr>
</tbody>
</table>

**Definitions of Decision Determinations**

**Medically Necessary:** Services that are Medically Necessary include only those which have been established as safe and effective, are furnished under generally accepted professional standards to treat illness, injury or medical condition, and which, as determined by Blue Shield, are: (a) consistent with Blue Shield medical policy; (b) consistent with the symptoms or diagnosis; (c) not furnished primarily for the convenience of the patient, the attending Physician or other provider; (d) furnished at the most appropriate level which can be provided safely and effectively to the patient; and (e) not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of the Member’s illness, injury, or disease.

**Investigational/Experimental:** A treatment, procedure, or drug is investigational when it has not been recognized as safe and effective for use in treating the particular condition in accordance with generally accepted professional medical standards. This includes services where approval by the federal or state governmental is required prior to use, but has not yet been granted.
**Split Evaluation:** Blue Shield of California/Blue Shield of California Life & Health Insurance Company (Blue Shield) policy review can result in a split evaluation, where a treatment, procedure, or drug will be considered to be investigational for certain indications or conditions, but will be deemed safe and effective for other indications or conditions, and therefore potentially medically necessary in those instances.

**Prior Authorization Requirements (as applicable to your plan)**

Within five days before the actual date of service, the provider must confirm with Blue Shield that the member's health plan coverage is still in effect. Blue Shield reserves the right to revoke an authorization prior to services being rendered based on cancellation of the member's eligibility. Final determination of benefits will be made after review of the claim for limitations or exclusions.

Questions regarding the applicability of this policy should be directed to the Prior Authorization Department at (800) 541-6652, or the Transplant Case Management Department at (800) 637-2066 ext. 3507708 or visit the provider portal at www.blueshieldca.com/provider.

Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. Blue Shield of California may consider published peer-reviewed scientific literature, national guidelines, and local standards of practice in developing its medical policy. Federal and state law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over medical policy and must be considered first in determining covered services. Member contracts may differ in their benefits. Blue Shield reserves the right to review and update policies as appropriate.